EE385 Cost and Health Care Resource Utilization (HCRU) in Patients Starting Intravitreal Dexamethasone (DEX) or ANTI-Vascular Endothelial Growth Factor (AVEGF) in Patients with Diabetic Macular Edema (DME)
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.633
https://www.valueinhealthjournal.com/article/S1098-3015(22)00834-8/fulltext
Title :
EE385 Cost and Health Care Resource Utilization (HCRU) in Patients Starting Intravitreal Dexamethasone (DEX) or ANTI-Vascular Endothelial Growth Factor (AVEGF) in Patients with Diabetic Macular Edema (DME)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00834-8&doi=10.1016/j.jval.2022.04.633
First page :
Section Title :
Open access? :
No
Section Order :
10565